Part 2: A Phase 2a, Single-Blind, Placebo Run-In, Multiple-Dose Safety Study to Evaluate the Safety, Tolerability, and PK of LQT-1213 in Patients Diagnosed with LQT1, LQT2 or LQT3.
Part 2: A Phase 2a, Single-Blind, Placebo Run-In, Multiple-Dose Safety Study to Evaluate the Safety, Tolerability, and PK of LQT-1213 in Patients Diagnosed with LQT1, LQT2 or LQT3.